Last Updated: 07/07/2025

Establishment of drug development and commercial manufacturing of malaria vaccine

Objectives

This project aims to develop NPC-SE36, which is a preventive vaccine using the recombinant SE36 protein of SERA5 protein, which has almost no genetic polymorphism in Plasmodium falciparum, as an antigen.

Principal Institution

Nobelpharma Co. Ltd., Japan

Principal Investigators / Focal Persons

Masanori Koshisakabe

Rationale and Abstract

NPC-SE36 has obtained regulatory approval for use in developing countries such as Africa as an effective preventive measure against Plasmodium falciparum vaccine, which is one of the three major infectious diseases in the world, with the aim of contributing to global health. The team is proceeding with development with the aim of acquiring two indications for “travelers.” So far, safety in humans has been confirmed, and data on protective effects exceeding 70% have been obtained, and establishment of commercial manufacturing and clinical trials are being planned and implemented for practical use.

Themes

Product Development
Vaccines

Date

Apr 2017 — Mar 2018

Total Project Funding

$223,759

Funding Details

Japan Agency for Medical Research and Development (AMED), Japan

Grant ID: 17pc0101008h0001

JPY 25M

Country / Project Site(s)

Japan